MedPath

RELENZA

These highlights do not include all the information needed to use RELENZA safely and effectively. See full prescribing information for RELENZA. RELENZA (zanamivir) Inhalation Powder, for oral inhalationInitial U.S. Approval: 1999

Approved
Approval ID

315556f2-4da0-47fc-86af-8fb61f6dd3bf

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 2, 2010

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

zanamivir

PRODUCT DETAILS

NDC Product Code54868-4377
Application NumberNDA021036
Marketing CategoryC73594
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateMay 18, 2011
Generic Namezanamivir

INGREDIENTS (2)

ZANAMIVIRActive
Quantity: 5 mg in 1 1
Code: L6O3XI777I
Classification: ACTIB
LACTOSEInactive
Code: J2B2A4N98G
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

RELENZA - FDA Drug Approval Details